Sox17 Regulates Liver Lipid Metabolism and Adaptation to Fasting

Rommelaere, Samuel; Millet, Virginie; Vu Manh, Thien-Phong; Gensollen, Thomas; Andreoletti, Pierre; Cherkaoui-Malki, Mustapha; Bourges, Christophe; Escalière, Bertrand; Du, Xin; Xia, Yu; Imbert, Jean; Beutler, Bruce; Kanai, Yoshiakira; Malissen, Bernard; Malissen, Marie; Tailleux, Anne; Staels, Bart; Galland, Franck; Naquet, Philippe
August 2014
PLoS ONE;Aug2014, Vol. 9 Issue 8, p1
Academic Journal
Liver is a major regulator of lipid metabolism and adaptation to fasting, a process involving PPARalpha activation. We recently showed that the Vnn1 gene is a PPARalpha target gene in liver and that release of the Vanin-1 pantetheinase in serum is a biomarker of PPARalpha activation. Here we set up a screen to identify new regulators of adaptation to fasting using the serum Vanin-1 as a marker of PPARalpha activation. Mutagenized mice were screened for low serum Vanin-1 expression. Functional interactions with PPARalpha were investigated by combining transcriptomic, biochemical and metabolic approaches. We characterized a new mutant mouse in which hepatic and serum expression of Vanin-1 is depressed. This mouse carries a mutation in the HMG domain of the Sox17 transcription factor. Mutant mice display a metabolic phenotype featuring lipid abnormalities and inefficient adaptation to fasting. Upon fasting, a fraction of the PPARα-driven transcriptional program is no longer induced and associated with impaired fatty acid oxidation. The transcriptional phenotype is partially observed in heterozygous Sox17+/− mice. In mutant mice, the fasting phenotype but not all transcriptomic signature is rescued by the administration of the PPARalpha agonist fenofibrate. These results identify a novel role for Sox17 in adult liver as a modulator of the metabolic adaptation to fasting.


Related Articles

  • CME Events.  // South Dakota Medicine;May2014, Vol. 67 Issue 5, p214 

    A calendar of Continuing Medical Education events throughout the U. S. from May 5-9 to September 18-19, 2014 is presented which includes basic to advanced echocardiology, effective clinical management of borderline personality disorder and Mayo clinic gastroenterology and hepatology board review.

  • Hepatobiliary Quiz-10 (2014) Multiple Choice Questions. Agrawal, Swastik; Dhiman, Radha K. // Experimental & Clinical Hepatology;Jun2014, Vol. 4 Issue 2, p182 

    A quiz concerning topics related to hepatology is presented.

  • Hepatobiliary Quiz-10 (2014) Answers to Multiple Choice Questions. Agrawal, Swastik; Dhiman, Radha K. // Experimental & Clinical Hepatology;Jun2014, Vol. 4 Issue 2, p184 

    The article provides answers to the quiz concerning hepatology.

  • Dysplastic Hepatocytes Develop Nuclear Inclusions in a Mouse Model of Viral Hepatitis. Thakur, Priyanka; Lamoke, Folami; Chaffin, Joanna M.; Bartoli, Manuela; Lee, Jeffrey R.; Duncan, Michael B. // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    Viral hepatitis resulting in chronic liver disease is an important clinical challenge and insight into the cellular processes that drive pathogenesis will be critical in order to develop new diagnostic and therapeutic options. Nuclear inclusions in viral and non-viral hepatitis are well...

  • Hydrodynamic tail vein injection of SOCS3 eukaryotic expression vector in vivo promoted liver lipid metabolism and hepatocyte apoptosis in mouse. Liu, Zhenjiang; Gan, Lu; Yang, Xiaobo; Zhang, Zhenzhen; Sun, Chao // Biochemistry & Cell Biology;Apr2014, Vol. 92 Issue 2, p119 

    Suppressor of cytokine signaling 3 (SOCS3), a signal transduction cytokine, is involved in lipid metabolism as well as in cell proliferation, differentiation, apoptosis, and so on. To explore the effects of SOCS3 on apoptosis and lipid metabolism in liver, we used a simple effective method named...

  • l-Carnitine induces recovery of liver lipid metabolism in cancer cachexia. Silvério, Renata; Laviano, Alessandro; Fanelli, Filippo; Seelaender, Marília // Amino Acids;May2012, Vol. 42 Issue 5, p1783 

    Cancer cachexia causes metabolic alterations with a marked effect on hepatic lipid metabolism. l-Carnitine modulates lipid metabolism and its supplementation has been proposed as a therapeutic strategy in many diseases. In the present study, the effects of l-carnitine supplementation on gene...

  • Oral Exposure of Mice to Carbendazim Induces Hepatic Lipid Metabolism Disorder and Gut Microbiota Dysbiosis. Yuanxiang Jin; Zhaoyang Zeng; Yan Wu; Songbin Zhang; Zhengwei Fu // Toxicological Sciences;Sep2015, Vol. 147 Issue 1, p116 

    Carbendazim (CBZ) has been considered as an endocrine disruptor that caused mammalian toxicity in different endpoints. Here, we revealed that oral administrations with CBZ at 100 and 500 mg/kg body weight for 28 days induced hepatic lipid metabolism disorder which was characterized by...

  • Gastric bezoars – diagnostic and therapeutic challenges. Mihai, Catalina; Mihai, Bogdan; Drug, Vasile; Prelipcean, Cristina Cijevschi // Journal of Gastrointestinal & Liver Diseases;Mar2013, Vol. 22 Issue 1, p111 

    A letter to the editor is presented which discusses the diagnostic and therapeutic challenges of gastric bezoars in the Institute of Gastroenterology and Hepatology in Iasi, Romania.

  • Gastroenterology: Gastroenterology, CGH maintain strong 2011 impact factors.  // Biomedical Market Newsletter;7/19/2012, Vol. 21, p1 

    The article informs that the American Gastroenterological Association journals including the journal "Gastroenterology" and journal "Clinical Gastroenterology and Hepatology" retained their position with rank 1 and rank 8 for the year 2011.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics